KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $24.8 million.

  • Supernus Pharmaceuticals' Depreciation & Amortization (CF) rose 2340.07% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.4 million, marking a year-over-year increase of 257.91%. This contributed to the annual value of $80.4 million for FY2024, which is 523.81% down from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Depreciation & Amortization (CF) is $24.8 million, which was up 2340.07% from $21.4 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $24.8 million for Q3 2025, and its period low was $6.6 million during Q1 2021.
  • Over the past 5 years, Supernus Pharmaceuticals' median Depreciation & Amortization (CF) value was $20.7 million (recorded in 2023), while the average stood at $18.4 million.
  • Over the last 5 years, Supernus Pharmaceuticals' Depreciation & Amortization (CF) had its largest YoY gain of 28060.05% in 2021, and its largest YoY loss of 1489.23% in 2021.
  • Quarter analysis of 5 years shows Supernus Pharmaceuticals' Depreciation & Amortization (CF) stood at $12.7 million in 2021, then skyrocketed by 64.07% to $20.8 million in 2022, then increased by 3.97% to $21.7 million in 2023, then dropped by 13.06% to $18.8 million in 2024, then skyrocketed by 31.63% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, $21.4 million for Q2 2025, and $20.4 million during Q1 2025.